Gallbladder Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against gallbladder cancer and guarantee the finest results for our customers all over the world.
Gallbladder Cancer
Gallbladder cancer is a relatively rare cancer. It is thought to be associated with the building up of gallstones and may also cause gallbladder calcification, a situation known as porcelain gall bladder, which is also rare. Some studies show that patients with porcelain gallbladder have a high risk of developing gallbladder cancer, but other studies have questioned this. It has a unique geographical distribution in Central and Eastern Europe, Japan and northern India, Central and South America. It is also common among certain ethnic groups such as Hispanic and Native American Indians. If diagnosed early, it can be cured by resection of the gallbladder, part of the liver, and the associated lymph nodes. It is mostly found after abdominal pain, jaundice and vomiting and other symptoms, and has already spread to the liver and other organs. If cancer is found after symptoms have started to occur, the 5-year survival rate is close to 3% and the prospect is not good for recovery.
Therapeutic Vaccines for Gallbladder Cancer
Immunotherapy holds good promise in non-responding cancers treated by conventional chemotherapeutic agents. Among various therapies, dendritic cell vaccine therapy is growing at rapid pace due to its acceptable rationale. It has been utilized in treating successfully resected stage III (T2, N1, M0) gallbladder cancer in some of the patients. Immunotherapy, especially dendritic cell therapy is expected to give good results in stage IV cancer. Most of the trials are conducted during this stage of disease where no therapy can be a guarantee of cure. A 48 years old lady treated with this therapy is free of metastasis with ten doses of autologous dendritic cell vaccine constructed by utilizing resected tumor lysate antigen. She has received ten doses of therapy in 14 months of her treatment. This therapy has proven to be safe and without apparent side effects. The positive clinical response obtained supports that autologous dendritic cell-based immunotherapy is a promising therapeutic approach for refractory gallbladder cancers. The diagnosis of gallbladder cancer should not be approached with a fatalistic attitude, as appropriate workup, extended resection and newer approaches including dendritic cell therapy can extend quality of life with chances of cure.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the gallbladder cancer vaccines. If you are interested in our services, please contact us for more details.
Reference
- Khan, JA. (2006). “Successful immunological treatment of gallbladder cancer in India--case report.” J Zhejiang Univ Sci B 7(9), 719-724.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
